STOCK TITAN

[8-K/A] GlucoTrack, Inc. Amends Material Event Report

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
8-K/A
Rhea-AI Filing Summary

Callan JMB Inc. (CJMB) has entered into a $25 million Equity Line of Credit (ELOC) with a single investor. Over an 18-month term, the company may, at its sole discretion, issue Regular Purchase notices of $0.5-$2.0 million per draw at 95 % of the lowest daily VWAP during a defined measurement period (80 % if CJMB is delisted from Nasdaq). An additional Exemption Purchase option allows draws up to $1 million on similar pricing, plus the investor receives bonus shares equal to 10 % of each exemption draw.

To secure the facility CJMB will issue 15,000 commitment shares and cap the investor’s ownership at 4.99 %. Failure to file or have declared effective an S-1 covering resale of the ELOC and commitment shares within the agreed deadlines triggers a 25,000-share penalty for each breach. All sales are exempt from registration under Section 4(a)(2) until the registration statement is effective. The agreement provides flexible, on-demand financing but could create dilution because shares are sold at a discount and additional shares may be issued as penalties or bonuses.

Callan JMB Inc. (CJMB) ha stipulato una Linea di Credito Azionaria (ELOC) da 25 milioni di dollari con un singolo investitore. Nel corso di un periodo di 18 mesi, la società potrà, a sua esclusiva discrezione, emettere avvisi di acquisto regolari da 0,5 a 2,0 milioni di dollari per ogni prelievo, al 95% del VWAP giornaliero più basso durante un periodo di misurazione definito (80% se CJMB viene esclusa dal Nasdaq). Un'ulteriore opzione di Acquisto Esente consente prelievi fino a 1 milione di dollari a prezzi simili, oltre a che l'investitore riceve azioni bonus pari al 10% di ogni prelievo esente.

Per garantire la linea di credito, CJMB emetterà 15.000 azioni di impegno e limiterà la proprietà dell'investitore al 4,99%. Il mancato deposito o la mancata efficacia di un modulo S-1 che copra la rivendita dell'ELOC e delle azioni di impegno entro le scadenze concordate comporta una penalità di 25.000 azioni per ogni violazione. Tutte le vendite sono esenti da registrazione ai sensi della Sezione 4(a)(2) fino a quando la dichiarazione di registrazione non è efficace. L'accordo offre un finanziamento flessibile e su richiesta, ma potrebbe causare diluizione poiché le azioni vengono vendute a sconto e potrebbero essere emesse ulteriori azioni come penalità o bonus.

Callan JMB Inc. (CJMB) ha firmado una Línea de Crédito de Capital (ELOC) de 25 millones de dólares con un único inversor. Durante un plazo de 18 meses, la compañía podrá, a su entera discreción, emitir avisos de compra regulares de 0,5 a 2,0 millones de dólares por cada extracción al 95 % del VWAP diario más bajo durante un período de medición definido (80 % si CJMB es excluida de Nasdaq). Una opción adicional de Compra Exenta permite extracciones de hasta 1 millón de dólares con precios similares, además el inversor recibe acciones de bonificación equivalentes al 10 % de cada extracción exenta.

Para asegurar la facilidad, CJMB emitirá 15,000 acciones de compromiso y limitará la propiedad del inversor al 4,99 %. El incumplimiento en presentar o hacer efectiva una declaración S-1 que cubra la reventa del ELOC y las acciones de compromiso dentro de los plazos acordados genera una penalización de 25,000 acciones por cada incumplimiento. Todas las ventas están exentas de registro bajo la Sección 4(a)(2) hasta que la declaración de registro sea efectiva. El acuerdo proporciona financiamiento flexible y bajo demanda, pero podría causar dilución porque las acciones se venden con descuento y pueden emitirse acciones adicionales como penalizaciones o bonificaciones.

Callan JMB Inc. (CJMB)는 단일 투자자와 2,500만 달러 규모의 주식 신용 한도(ELOC) 계약을 체결했습니다. 18개월 기간 동안 회사는 전적으로 자율적으로, 정의된 측정 기간 동안 하루 최저 VWAP의 95% 가격으로 50만~200만 달러 규모의 정규 매수 통지를 발행할 수 있습니다(만약 CJMB가 나스닥에서 상장 폐지될 경우 80%). 추가 면제 매수 옵션은 유사한 가격으로 최대 100만 달러까지 인출할 수 있으며, 투자자는 각 면제 인출액의 10%에 해당하는 보너스 주식을 받습니다.

이 시설을 확보하기 위해 CJMB는 15,000개의 약정 주식을 발행하고 투자자의 소유 지분을 4.99%로 제한합니다. ELOC 및 약정 주식의 재판매를 다루는 S-1 서류를 합의된 기한 내에 제출하거나 효력이 발생하지 못하면 위반당 25,000주의 벌칙이 부과됩니다. 모든 판매는 등록 명세서가 효력을 발휘할 때까지 섹션 4(a)(2)에 따라 등록 면제를 받습니다. 이 계약은 유연하고 필요에 따라 자금을 조달할 수 있지만, 주식이 할인된 가격에 판매되고 벌칙이나 보너스로 추가 주식이 발행될 수 있어 희석 효과가 발생할 수 있습니다.

Callan JMB Inc. (CJMB) a conclu une ligne de crédit en actions (ELOC) de 25 millions de dollars avec un investisseur unique. Sur une période de 18 mois, la société peut, à sa seule discrétion, émettre des avis d'achat réguliers de 0,5 à 2,0 millions de dollars par tirage à 95 % du VWAP journalier le plus bas pendant une période de mesure définie (80 % si CJMB est radiée du Nasdaq). Une option d'achat supplémentaire exonérée permet des tirages jusqu'à 1 million de dollars à des prix similaires, et l'investisseur reçoit des actions bonus équivalentes à 10 % de chaque tirage exonéré.

Pour garantir la facilité, CJMB émettra 15 000 actions d'engagement et limitera la participation de l'investisseur à 4,99 %. Le défaut de dépôt ou de mise en vigueur d'un formulaire S-1 couvrant la revente de l'ELOC et des actions d'engagement dans les délais convenus entraîne une pénalité de 25 000 actions par infraction. Toutes les ventes sont exemptées d'enregistrement en vertu de la section 4(a)(2) jusqu'à l'entrée en vigueur de la déclaration d'enregistrement. L'accord offre un financement flexible à la demande, mais pourrait entraîner une dilution car les actions sont vendues à prix réduit et des actions supplémentaires peuvent être émises en tant que pénalités ou primes.

Callan JMB Inc. (CJMB) hat eine 25-Millionen-Dollar-Aktienkreditlinie (ELOC) mit einem einzelnen Investor abgeschlossen. Über einen Zeitraum von 18 Monaten kann das Unternehmen nach eigenem Ermessen regelmäßige Kaufmitteilungen über 0,5 bis 2,0 Millionen Dollar pro Abruf zu 95 % des niedrigsten täglichen VWAP während eines definierten Messzeitraums ausgeben (80 %, falls CJMB von der Nasdaq delistet wird). Eine zusätzliche Ausnahme-Kaufoption erlaubt Abrufe bis zu 1 Million Dollar zu ähnlichen Preisen, zudem erhält der Investor Bonusaktien in Höhe von 10 % jedes Ausnahmepreises.

Zur Sicherung der Einrichtung wird CJMB 15.000 Verpflichtungsaktien ausgeben und den Anteil des Investors auf 4,99 % begrenzen. Wird eine S-1-Anmeldung für den Weiterverkauf der ELOC- und Verpflichtungsaktien nicht fristgerecht eingereicht oder wirksam, wird pro Verstoß eine Strafe von 25.000 Aktien fällig. Alle Verkäufe sind gemäß Abschnitt 4(a)(2) bis zur Wirksamkeit der Registrierungserklärung von der Registrierung befreit. Die Vereinbarung bietet flexible, bedarfsorientierte Finanzierung, kann jedoch zu Verwässerung führen, da Aktien mit Abschlag verkauft werden und zusätzliche Aktien als Strafen oder Boni ausgegeben werden können.

Positive
  • Access to up to $25 million in flexible, on-demand equity financing, improving liquidity without increasing debt.
  • 4.99 % ownership cap limits control risk from the financing counterparty.
  • No obligation to draw; management can time capital raises based on market conditions.
Negative
  • Shares sold at 5-20 % discount to VWAP, creating immediate dilution and potential downward price pressure.
  • Commitment, bonus and penalty shares increase share count even without cash proceeds.
  • Registration statement deadlines carry 25 k-share penalties, adding execution risk.

Insights

TL;DR: Optional $25 m ELOC boosts liquidity but adds discounted share supply and dilution risk.

The facility gives CJMB rapid access to capital without upfront debt service, helpful for working-capital or growth needs. Pricing at 95 % of VWAP is in line with small-cap PIPE norms, yet still dilutive and potentially pressures the share price, especially if draw frequency is high. The 4.99 % cap prevents a change of control, but commitment, bonus and penalty shares embed additional dilution. Timely filing of the resale S-1 is critical to avoid issuing 25 k penalty shares. Overall, the agreement is neutral-to-slightly positive for liquidity, negative for existing shareholders’ ownership percentage.

TL;DR: Governance safeguards exist, but discounted share issuance raises dilution and market-impact concerns.

The Purchase and Registration Rights agreements use standard reps & warranties and a sub-5 % ownership cap, limiting concentration risk. However, discount mechanics (up to 20 % if Nasdaq listing is lost) and mandatory bonus shares for exemption purchases incentivize repeated draws that may depress trading prices. Penalty-share clauses for late registration create additional downside. Investors should monitor management’s capital planning discipline and registration timeline adherence. Impact classified as neutral; beneficial to solvency but with notable shareholder dilution risk.

Callan JMB Inc. (CJMB) ha stipulato una Linea di Credito Azionaria (ELOC) da 25 milioni di dollari con un singolo investitore. Nel corso di un periodo di 18 mesi, la società potrà, a sua esclusiva discrezione, emettere avvisi di acquisto regolari da 0,5 a 2,0 milioni di dollari per ogni prelievo, al 95% del VWAP giornaliero più basso durante un periodo di misurazione definito (80% se CJMB viene esclusa dal Nasdaq). Un'ulteriore opzione di Acquisto Esente consente prelievi fino a 1 milione di dollari a prezzi simili, oltre a che l'investitore riceve azioni bonus pari al 10% di ogni prelievo esente.

Per garantire la linea di credito, CJMB emetterà 15.000 azioni di impegno e limiterà la proprietà dell'investitore al 4,99%. Il mancato deposito o la mancata efficacia di un modulo S-1 che copra la rivendita dell'ELOC e delle azioni di impegno entro le scadenze concordate comporta una penalità di 25.000 azioni per ogni violazione. Tutte le vendite sono esenti da registrazione ai sensi della Sezione 4(a)(2) fino a quando la dichiarazione di registrazione non è efficace. L'accordo offre un finanziamento flessibile e su richiesta, ma potrebbe causare diluizione poiché le azioni vengono vendute a sconto e potrebbero essere emesse ulteriori azioni come penalità o bonus.

Callan JMB Inc. (CJMB) ha firmado una Línea de Crédito de Capital (ELOC) de 25 millones de dólares con un único inversor. Durante un plazo de 18 meses, la compañía podrá, a su entera discreción, emitir avisos de compra regulares de 0,5 a 2,0 millones de dólares por cada extracción al 95 % del VWAP diario más bajo durante un período de medición definido (80 % si CJMB es excluida de Nasdaq). Una opción adicional de Compra Exenta permite extracciones de hasta 1 millón de dólares con precios similares, además el inversor recibe acciones de bonificación equivalentes al 10 % de cada extracción exenta.

Para asegurar la facilidad, CJMB emitirá 15,000 acciones de compromiso y limitará la propiedad del inversor al 4,99 %. El incumplimiento en presentar o hacer efectiva una declaración S-1 que cubra la reventa del ELOC y las acciones de compromiso dentro de los plazos acordados genera una penalización de 25,000 acciones por cada incumplimiento. Todas las ventas están exentas de registro bajo la Sección 4(a)(2) hasta que la declaración de registro sea efectiva. El acuerdo proporciona financiamiento flexible y bajo demanda, pero podría causar dilución porque las acciones se venden con descuento y pueden emitirse acciones adicionales como penalizaciones o bonificaciones.

Callan JMB Inc. (CJMB)는 단일 투자자와 2,500만 달러 규모의 주식 신용 한도(ELOC) 계약을 체결했습니다. 18개월 기간 동안 회사는 전적으로 자율적으로, 정의된 측정 기간 동안 하루 최저 VWAP의 95% 가격으로 50만~200만 달러 규모의 정규 매수 통지를 발행할 수 있습니다(만약 CJMB가 나스닥에서 상장 폐지될 경우 80%). 추가 면제 매수 옵션은 유사한 가격으로 최대 100만 달러까지 인출할 수 있으며, 투자자는 각 면제 인출액의 10%에 해당하는 보너스 주식을 받습니다.

이 시설을 확보하기 위해 CJMB는 15,000개의 약정 주식을 발행하고 투자자의 소유 지분을 4.99%로 제한합니다. ELOC 및 약정 주식의 재판매를 다루는 S-1 서류를 합의된 기한 내에 제출하거나 효력이 발생하지 못하면 위반당 25,000주의 벌칙이 부과됩니다. 모든 판매는 등록 명세서가 효력을 발휘할 때까지 섹션 4(a)(2)에 따라 등록 면제를 받습니다. 이 계약은 유연하고 필요에 따라 자금을 조달할 수 있지만, 주식이 할인된 가격에 판매되고 벌칙이나 보너스로 추가 주식이 발행될 수 있어 희석 효과가 발생할 수 있습니다.

Callan JMB Inc. (CJMB) a conclu une ligne de crédit en actions (ELOC) de 25 millions de dollars avec un investisseur unique. Sur une période de 18 mois, la société peut, à sa seule discrétion, émettre des avis d'achat réguliers de 0,5 à 2,0 millions de dollars par tirage à 95 % du VWAP journalier le plus bas pendant une période de mesure définie (80 % si CJMB est radiée du Nasdaq). Une option d'achat supplémentaire exonérée permet des tirages jusqu'à 1 million de dollars à des prix similaires, et l'investisseur reçoit des actions bonus équivalentes à 10 % de chaque tirage exonéré.

Pour garantir la facilité, CJMB émettra 15 000 actions d'engagement et limitera la participation de l'investisseur à 4,99 %. Le défaut de dépôt ou de mise en vigueur d'un formulaire S-1 couvrant la revente de l'ELOC et des actions d'engagement dans les délais convenus entraîne une pénalité de 25 000 actions par infraction. Toutes les ventes sont exemptées d'enregistrement en vertu de la section 4(a)(2) jusqu'à l'entrée en vigueur de la déclaration d'enregistrement. L'accord offre un financement flexible à la demande, mais pourrait entraîner une dilution car les actions sont vendues à prix réduit et des actions supplémentaires peuvent être émises en tant que pénalités ou primes.

Callan JMB Inc. (CJMB) hat eine 25-Millionen-Dollar-Aktienkreditlinie (ELOC) mit einem einzelnen Investor abgeschlossen. Über einen Zeitraum von 18 Monaten kann das Unternehmen nach eigenem Ermessen regelmäßige Kaufmitteilungen über 0,5 bis 2,0 Millionen Dollar pro Abruf zu 95 % des niedrigsten täglichen VWAP während eines definierten Messzeitraums ausgeben (80 %, falls CJMB von der Nasdaq delistet wird). Eine zusätzliche Ausnahme-Kaufoption erlaubt Abrufe bis zu 1 Million Dollar zu ähnlichen Preisen, zudem erhält der Investor Bonusaktien in Höhe von 10 % jedes Ausnahmepreises.

Zur Sicherung der Einrichtung wird CJMB 15.000 Verpflichtungsaktien ausgeben und den Anteil des Investors auf 4,99 % begrenzen. Wird eine S-1-Anmeldung für den Weiterverkauf der ELOC- und Verpflichtungsaktien nicht fristgerecht eingereicht oder wirksam, wird pro Verstoß eine Strafe von 25.000 Aktien fällig. Alle Verkäufe sind gemäß Abschnitt 4(a)(2) bis zur Wirksamkeit der Registrierungserklärung von der Registrierung befreit. Die Vereinbarung bietet flexible, bedarfsorientierte Finanzierung, kann jedoch zu Verwässerung führen, da Aktien mit Abschlag verkauft werden und zusätzliche Aktien als Strafen oder Boni ausgegeben werden können.

true 0001506983 0001506983 2025-07-18 2025-07-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 18, 2025

 

GLUCOTRACK, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-41141   98-0668934
(State or Other Jurisdiction   (Commission   (IRS Employer
of Incorporation)   File Number)   Identification No.)

 

301 Rte. 17 North, Ste. 800, Rutherford, NJ   07070
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (201) 842-7715

 

N/A

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GCTK   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

EXPLANATORY NOTE

 

On July 24, 2025, Glucotrack, Inc. (the “Company”), filed with the Securities and Exchange Commission (the “SEC”) a Current Report on Form 8-K (the “Original 8-K”) to disclose, among other things, that the Company had terminated its engagement of Fahn Kanne & Co. Grant Thornton Israel (“Grant Thornton”) as the Company’s independent registered public accounting, effective immediately. Prior to filing the Original 8-K, the Company provided Grant Thornton with a copy of the disclosure contained in the Original 8-K, and requested that Grant Thornton furnish the Company a letter addressed to the SEC stating whether or not it agreed with the statements therein and, if not, stating the respects in which it did not agree (the “Auditor Letter”). As of July 24, 2025, the date on which the Original 8-K was filed, the Company had not yet received the Auditor Letter from Grant Thornton.

 

On July 25, 2025, Grant Thornton furnished the Company with the Auditor Letter. The Company is filing this Amendment No. 1 to the Original 8-K (the “Amendment”) solely to amend Item 4.01 and provide the Auditor Letter as an exhibit to this filing.

 

Except as expressly noted above, this Amendment does not modify or update in any way disclosures made in the Original 8-K. Accordingly, this Amendment should be read in conjunction with the Original 8-K.

 

 
 

 

Item 4.01. Changes in Registrant’s Certifying Accountant.

 

(a) Dismissal of Independent Registered Public Accounting Firm.

 

On July 18, the Audit Committee (the “Audit Committee”) of the board of directors (the “Board”) of the Company approved the engagement of CBIZ CPAs P.C. (“CBIZ”) as the Company’s independent registered public accounting firm for the Company’s fiscal year ended December 31, 2025, effective July 18, 2025. On July 18, 2025, the Company dismissed Grant Thornton as the Company’s independent registered public accounting firm, effective immediately.

 

The reports of Grant Thornton on the Company’s financial statements for either of the past two years did not contain an adverse opinion or a disclaimer of opinion, and were not qualified or modified as to uncertainty, audit scope or accounting principles, other than including an explanatory paragraph regarding substantial doubt about the Company’s ability to continue as a going concern.

 

During the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through July 18, 2025, there have been no “disagreements” (as defined in Item 304(a)(1)(iv) of Regulation S-K and related instructions) with Grant Thornton on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements if not resolved to the satisfaction of Grant Thornton would have caused Grant Thornton to make reference thereto in its reports on the consolidated financial statements for such years.

 

As disclosed in the Form 10-K for the year ended December 31, 2024, the management identified material weaknesses in internal control over financial reporting related to general IT controls, lack of sufficient accounting personnel, and inadequate segregation of duties, Other than these internal control matters, there were no reportable events (as that term is described in Item 304(a)(1)(v) of Regulation S-K and related instructions) during the fiscal years ended December 31, 2024 and 2023, and the subsequent interim period through July 18, 2025. The Audit Committee discussed the Company’s material weaknesses in internal control over financial reporting with Grant Thornton and the Company has authorized Grant Thornton to respond fully to any inquiries of the Company’s new independent registered public accounting firm, CBIZ concerning the subject matter of these material weaknesses.

 

The Company provided Grant Thornton with a copy of the disclosure it is making herein in response to Item 304(a) of Regulation S-K, and requested that Grant Thornton furnish the Company with a letter addressed to the Securities and Exchange Commission, pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not Grant Thornton agrees with the statements related to them made by the Company in this report. A copy of Grant Thornton’s letter is filed as Exhibit 16.1 to this Current Report on Form 8-K.

 

(b) Engagement of New Independent Registered Public Accounting Firm.

 

As disclosed above, on July 18, 2025, the Audit Committee of the Board approved the engagement of CBIZ as the Company’s independent registered public accounting firm for the Company’s fiscal year ended December 31, 2025, effective July 18, 2025.

 

During the fiscal years ended December 31, 2024 and 2023 and through July 18, 2025, neither the Company, nor anyone on its behalf, consulted CBIZ regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered with respect to the consolidated financial statements of the Company, and no written report or oral advice was provided to the Company by CBIZ that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was the subject of a “disagreement” (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit No.   Description
16.1   Letter from Fahn Kanne & Co. Grant Thornton Israel, dated July 25, 2025
104   Cover Page Interactive Data File (embedded within the inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: July 25, 2025  
   
  GLUCOTRACK, INC.
   
  By: /s/ Paul Goode
  Name: Paul Goode
  Title: Chief Executive Officer

 

 

FAQ

How much capital can Callan JMB (CJMB) raise under the new ELOC?

The company may sell up to $25 million of common stock to the investor over an 18-month term.

At what price will CJMB shares be sold to the investor?

Regular and exemption purchases are priced at 95 % of the lowest daily VWAP in the measurement period (80 % if delisted).

What dilution protections exist for existing CJMB shareholders?

The investor’s stake is capped at 4.99 %, but discounted pricing and bonus shares still dilute current holders.

What happens if CJMB misses the registration filing deadline?

The company must issue an additional 25,000 shares to the investor if it fails to file or make effective the registration statement on time.

Is CJMB obligated to use the ELOC?

No. Management decides whether and when to issue purchase notices; the facility is purely discretionary.
Glucotrack

NASDAQ:GCTK

GCTK Rankings

GCTK Latest News

GCTK Latest SEC Filings

GCTK Stock Data

4.70M
492.46k
2.34%
0.43%
7.56%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
RUTHERFORD